Regulation of angiotensinogen production by angiotensin II analogues. 1988

I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
INSERM U36, Paris, France.

Specific binding sites for angiotensin II (Ang II) were identified in a human hepatoma cell line, HepG2. Binding of [125I]-Sar1 Ang II to these cells showed a high-affinity site with a Kd of 2.4 +/- 0.2 nmol/l. This specific binding was not changed during the cell cycle and showed no alteration after 24 h of treatment with Sar1-Ang II (10(-8) mol/l). Exposure of HepG2 cells to the Ang II agonist Sar1-Ang II caused a dose-dependent decrease in angiotensinogen production. The maximal inhibitory effect was at a dose of 10(-6) mol/l Sar1-Ang II which elicited 67% inhibition of angiotensinogen production after 24 h (control: 2.015 +/- 0.5 micrograms angiotensinogen/mg DNA; Sar1-Ang II 10(-6) mol/l: 0.68 +/- 0.03 micrograms angiotensinogen/mg DNA). Fifty per cent inhibition was obtained at a dose of 10(-9) mol/l Sar1-Ang II. Angiotensin II had a less marked effect, showing maximal inhibition of 40%. This study shows that the HepG2 cells possess specific Ang II binding sites and that Ang II analogues induce a dose-dependent inhibition of angiotensinogen production in cell culture.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000808 Angiotensinogen An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver in response to lowered blood pressure and secreted into blood circulation. Angiotensinogen is the inactive precursor of the ANGIOTENSINS produced in the body by successive enzyme cleavages. Cleavage of angiotensinogen by RENIN yields the decapeptide ANGIOTENSIN I. Further cleavage of angiotensin I (by ANGIOTENSIN CONVERTING ENZYME) yields the potent vasoconstrictor octapeptide ANGIOTENSIN II; and then, via other enzymes, other angiotensins also involved in the hemodynamic-regulating RENIN-ANGIOTENSIN SYSTEM. Hypertensinogen,Renin-Substrate,SERPINA8,Proangiotensin,Renin Substrate Tetradecapeptide,Serpin A8,Renin Substrate,Tetradecapeptide, Renin Substrate

Related Publications

I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
January 1990, Life sciences,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
October 2011, Journal of neurochemistry,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
January 1990, The American journal of physiology,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
March 1983, Circulation research,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
January 1990, Life sciences,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
February 1980, The American journal of physiology,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
December 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
November 1992, The American journal of physiology,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
July 2016, Brain research,
I A Darby, and E D Coezy, and J Mizrahi, and B Cantau, and M H Donnadieu, and J Nussberger, and P Corvol
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
Copied contents to your clipboard!